Capstone Investment Advisors LLC Takes $923,000 Position in ANI Pharmaceuticals, Inc. $ANIP

Capstone Investment Advisors LLC bought a new position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 11,150 shares of the specialty pharmaceutical company’s stock, valued at approximately $923,000.

A number of other hedge funds have also made changes to their positions in the company. KBC Group NV bought a new position in ANI Pharmaceuticals during the 1st quarter valued at about $28,000. Advisors Asset Management Inc. bought a new stake in ANI Pharmaceuticals during the first quarter worth about $28,000. Hantz Financial Services Inc. grew its stake in ANI Pharmaceuticals by 70.3% during the fourth quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock worth $48,000 after buying an additional 249 shares during the last quarter. Kemnay Advisory Services Inc. bought a new stake in ANI Pharmaceuticals during the fourth quarter worth about $48,000. Finally, State of Wyoming acquired a new stake in shares of ANI Pharmaceuticals during the second quarter worth approximately $50,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

Insider Transactions at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, SVP Ori Gutwerg sold 3,162 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $77.00, for a total transaction of $243,474.00. Following the transaction, the senior vice president directly owned 75,534 shares in the company, valued at approximately $5,816,118. This represents a 4.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Stephen P. Carey sold 3,313 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $86.00, for a total transaction of $284,918.00. Following the completion of the transaction, the chief financial officer directly owned 177,543 shares in the company, valued at $15,268,698. This trade represents a 1.83% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 24,387 shares of company stock worth $1,947,625. Corporate insiders own 8.10% of the company’s stock.

Analysts Set New Price Targets

ANIP has been the topic of several recent analyst reports. Wall Street Zen downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Weiss Ratings downgraded ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, August 11th. Guggenheim reduced their price objective on ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a research note on Monday, August 10th. Canaccord Genuity Group decreased their target price on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a report on Monday, August 10th. Finally, Zacks Research cut ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Four research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $105.83.

ANI Pharmaceuticals Trading Down 0.9%

Shares of NASDAQ ANIP opened at $72.83 on Friday. ANI Pharmaceuticals, Inc. has a 1-year low of $70.15 and a 1-year high of $99.50. The company has a 50-day moving average of $79.68 and a two-hundred day moving average of $78.65. The company has a market cap of $1.67 billion, a PE ratio of 15.70 and a beta of 0.44. The company has a current ratio of 2.91, a quick ratio of 2.41 and a debt-to-equity ratio of 0.99.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, beating the consensus estimate of $2.04 by $0.17. The business had revenue of $266.04 million for the quarter, compared to analysts’ expectations of $260.13 million. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. ANI Pharmaceuticals’s revenue was up 25.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.80 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, equities analysts expect that ANI Pharmaceuticals, Inc. will post 7.83 earnings per share for the current fiscal year.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.